Research

New findings from UVM researchers and colleagues describe the discovery of a unique dependence of cancer cells on a particular protein, which could lead to desperately-needed treatment for hard-to-treat cancers.

In developing therapies for hard-to-treat breast and ovarian cancers in patients with BRCA gene mutations, scientists aim to identify ways to keep cancer cells from using DNA break repair pathways. New findings from researchers including UVM Professor Sylvie Doublie demonstrate a previously-unknown capability for a key enzyme in this repair function that shows promise as a new avenue for treatment development.

​For Professor Elizabeth Bonney, M.D., M.P.H., juggling the roles of scientist, clinician, mentor, and advocate has been the norm for decades. So, it’s no surprise that in a year turned upside-down by the COVID-19 pandemic, the delayed reckoning with racial injustice in America, and political turmoil, she has forged ahead with her science, delivered care on the front lines, and used this pivotal moment in history to raise issues of critical importance not only to science, but society.

An interdisciplinary team of Vermont researchers and a partner at Yale's Smilow Cancer Center, conducted an economic evaluation to establish an overall cost-effectiveness comparison of two approaches to the treatment of low-volume metastatic prostate cancer. Their findings, published in JAMA Network Open, strongly support the addition of prostate radiation therapy to standard androgen deprivation therapy.

While public health and infectious disease experts have discussed strategies to enhance adherence, including the potential use of financial incentives, an examination of the scientific evidence on incentivizing vaccine adherence has not been discussed. A new Commentary in Preventive Medicine by Vermont Center on Behavior and Health Director Stephen Higgins, Ph.D., and colleagues addresses that gap.

A new study conducted by a team of health economists and public health faculty at the University of Vermont suggests that the behavior public officials are now mandating or recommending to slow the spread of COVID-19--wearing a face covering--should come with a caveat. If not accompanied by proper public education, the practice could lead to more infections.

The UVM Medical Center and Vaccine Testing Center have successfully reached and surpassed the targeted number of enrollees for an ongoing Phase 3 clinical trial of the AstraZeneca COVID-19 vaccine.

A study by UVM faculty members published in the Journal of the American Academy of Child and Adolescent Psychiatry reports that in a group of first-year university students, COVID-19 mitigation protocols had a modest, but persistent, impact on mood and wellness behaviors. Students enrolled in the university's wellness program, however, had improved mood levels and fewer attention problems.

A recent study conducted by collaborators from the University of Vermont and Cedars-Sinai describes the performance of South Burlington, Vt.-based Biocogniv’s new AI-COVID™ software.

Three University of Vermont professors, include Professor of Biochemistry Christopher Francklyn, Ph.D., have been named Fellows of the American Association for the Advancement of Science (AAAS), the world’s largest multidisciplinary scientific society, for their outstanding contributions to science.